PROCEPT BioRobotics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 01, 2023 at 08:11 pm
Share
PROCEPT BioRobotics Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 35.1 million compared to USD 20.35 million a year ago. Net loss was USD 24.62 million compared to USD 22.61 million a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.51 a year ago.
For the nine months, sales was USD 92.61 million compared to USD 51.24 million a year ago. Net loss was USD 78.39 million compared to USD 58.98 million a year ago. Basic loss per share from continuing operations was USD 1.7 compared to USD 1.33 a year ago.
PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Companyâs proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.
PROCEPT BIOROBOTICS CORPORATION 
